These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 22611636)
21. Novel mutation in an Egyptian patient with infantile Canavan disease. Zaki OK; El Abd HS; Mohamed SA; Zayed H Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958 [TBL] [Abstract][Full Text] [Related]
22. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population. Sistermans EA; de Coo RF; van Beerendonk HM; Poll-The BT; Kleijer WJ; van Oost BA Eur J Hum Genet; 2000 Jul; 8(7):557-60. PubMed ID: 10909858 [TBL] [Abstract][Full Text] [Related]
23. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Kaul R; Balamurugan K; Gao GP; Matalon R Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831 [TBL] [Abstract][Full Text] [Related]
24. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
25. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
26. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821 [TBL] [Abstract][Full Text] [Related]
27. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
29. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Matalon RM; Michals-Matalon K Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428 [TBL] [Abstract][Full Text] [Related]
30. Molecular basis of Canavan's disease: from human to mouse. Surendran S; Matalon KM; Tyring SK; Matalon R J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138 [TBL] [Abstract][Full Text] [Related]
31. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900 [TBL] [Abstract][Full Text] [Related]
32. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease. Surendran S Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702 [TBL] [Abstract][Full Text] [Related]
33. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
34. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. Kumar S; Biancotti JC; Matalon R; de Vellis J J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253 [TBL] [Abstract][Full Text] [Related]
35. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
36. Canavan disease: a white matter disorder. Kumar S; Mattan NS; de Vellis J Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907 [TBL] [Abstract][Full Text] [Related]
38. Feline Spongy Encephalopathy With a Mutation in the Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415 [TBL] [Abstract][Full Text] [Related]
39. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related]